Literature DB >> 19827323

Ethical considerations of genetic presymptomatic testing for Huntington's disease.

Alberto Coustasse1, Alicia Pekar, Andrew Sikula, Sue Lurie.   

Abstract

The aim of this literature review was to determine if there is adequate ethical justification for presymptomatic genetic testing on potential Huntington's disease patients. Huntington's disease is a neurological genetic disorder characterized by midlife onset which consists of cognitive, physical, and emotional deterioration. Although genetic testing has traditionally been guided by the principle of autonomy, severe psychological consequences such as depression, anxiety, survival guilt, and suicide have complicated the ethical issue of providing a presymptomatic yet definitive diagnosis for an incurable disease. An analysis of available articles yielded inconclusive findings, namely due to insufficient evidence, self-selection bias of test participants, or lack of a longitudinal design. Additional results indicated psychological distress is not solely associated with test result, but rather with individual characteristics including, but not limited to, psychological history, test motivation, level of preparation, social support, and age. In the interest of upholding the principles of autonomy, beneficence, nonmaleficence, and justice, it is recommended that medical professionals follow strict protocol, provide extensive counseling, and employ vigilance when assessing at-risk individuals for HD presymptomatic test eligibility to ensure psychological well-being.

Entities:  

Mesh:

Year:  2009        PMID: 19827323     DOI: 10.1080/15390940903041583

Source DB:  PubMed          Journal:  J Hosp Mark Public Relations        ISSN: 1539-0934


  7 in total

1.  Ethical dilemmas in genetic testing: examples from the Cuban program for predictive diagnosis of hereditary ataxias.

Authors:  Tania Cruz Mariño; Rubén Reynaldo Armiñán; Humberto Jorge Cedeño; José Miguel Laffita Mesa; Yanetza González Zaldivar; Raúl Aguilera Rodríguez; Miguel Velázquez Santos; Luis Enrique Almaguer Mederos; Milena Paneque Herrera; Luis Velázquez Pérez
Journal:  J Genet Couns       Date:  2011-01-25       Impact factor: 2.537

2.  Presymptomatic genetic testing in CADASIL.

Authors:  S Reyes; A Kurtz; D Hervé; E Tournier-Lasserve; H Chabriat
Journal:  J Neurol       Date:  2012-03-15       Impact factor: 4.849

Review 3.  What is the role of genetic testing in movement disorders practice?

Authors:  Susanne A Schneider; Christine Klein
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

Review 4.  Risk factors of suicidal ideation in Huntington's disease: literature review and data from Enroll-HD.

Authors:  Philipp Honrath; Imis Dogan; Olga Wudarczyk; Katharina S Görlich; Mikhail Votinov; Cornelius J Werner; Beate Schumann; Rena T Overbeck; Jörg B Schulz; Bernhard G Landwehrmeyer; Raquel E Gur; Ute Habel; Kathrin Reetz
Journal:  J Neurol       Date:  2018-08-27       Impact factor: 4.849

5.  'I Don't Like Uncertainty, I Like to Know': How and why uveal melanoma patients consent to life expectancy prognostication.

Authors:  Stephen L Brown; Peter L Fisher; Andrew Morgan; Cari Davies; Yasmin Olabi; Laura Hope-Stone; Heinrich Heimann; Rumana Hussain; Mary Gemma Cherry
Journal:  Health Expect       Date:  2022-04-26       Impact factor: 3.318

6.  How much diagnostic safety can we afford, and how should we decide? A health economics perspective.

Authors:  David E Newman-Toker; Kathryn M McDonald; David O Meltzer
Journal:  BMJ Qual Saf       Date:  2013-10       Impact factor: 7.035

7.  Is accurate routine cancer prognostication psychologically harmful? 5-year outcomes of life expectancy prognostication in uveal melanoma survivors.

Authors:  Stephen L Brown; Peter Fisher; Laura Hope-Stone; Bertil Damato; Heinrich Heimann; Rumana Hussain; M Gemma Cherry
Journal:  J Cancer Surviv       Date:  2021-04-19       Impact factor: 4.442

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.